marketNovember 17, 2026
AI for Drugs: Isomorphic Labs Secures $5 Billion

Isomorphic Labs, an Alphabet subsidiary, has successfully completed a Series C funding round, attracting $5 billion. The investment was led by Greenoaks and Sequoia Capital, valuing the AI drug discovery developer at approximately $50 billion. The funds will be allocated to further develop the advanced IsoDDE platform and to create proprietary drugs targeting oncological and immunological diseases.
Despite the impressive investment, Isomorphic Labs' developments are currently in the early, preclinical stage. The company's focus is on leveraging artificial intelligence to accelerate and reduce the cost of discovering and developing new medicines. Its technologies are designed to analyze vast datasets, predict molecule efficacy and safety, thereby shortening the time-to-market for new drugs.
The raised capital will enable Isomorphic Labs to scale its research, expand its team, and conduct necessary trials to advance its drug candidates. The successful attraction of such significant funding demonstrates high investor confidence in the potential of AI within the pharmaceutical industry. This could represent a significant step in revolutionizing approaches to treating complex diseases.
Such investments in AI startups highlight the growing interest in new technologies within healthcare. While cryptocurrency markets, like the ability to buy BTC for rubles or tracking Ethereum's course, attract separate attention, medical innovations also showcase immense future potential. For those interested in investment avenues, it is important to monitor the progress of both digital assets and breakthrough technologies in the real economy sector.
Reliable services play a crucial role in the modern financial world, whether for cryptocurrency exchange or other financial operations. In this context, Ruber offers users a dependable solution for their needs.